+44 (0)1509 263171
Please use this identifier to cite or link to this item:
|Title: ||The use of bioreactors as in vitro models in pharmaceutical research|
|Authors: ||Ginai, Maaria|
Hewitt, Christopher J.
|Issue Date: ||2013|
|Publisher: ||© Elsevier Ltd.|
|Citation: ||GINAI, M. ... et al., 2013. The use of bioreactors as in vitro models in pharmaceutical research. Drug Discovery Today, 18 (19-20), pp. 922 - 935.|
|Abstract: ||Bringing a new drug to market is costly in terms of capital and time investments, and any development issues encountered during late-stage clinical trials can often be the result of in vitro-in vivo extrapolations (IVIVE) not accurately reflecting clinical outcome. In the discipline of drug metabolism and pharmacokinetics (DMPK), current in vitro cellular methods do not provide the 3D structure and function of organs found in vivo; therefore, new dynamic methods need to be established to aid improvement of IVIVE. In this review, we highlight the importance of model progression into dynamic systems for use within drug development, focusing on devices developed currently in the areas of the liver and blood-brain barrier (BBB), and the potential to develop models for other organ systems, such as the kidney. We discuss the development of dynamic 3D bioreactor-based systems as in vitro models for use in DMPK studies.|
|Description: ||This article was published in the journal, Drug Discovery Today [© Elsevier Ltd.] and the definitive version is available at: http://dx.doi.org/10.1016/j.drudis.2013.05.016|
|Version: ||Submitted for publication|
|Publisher Link: ||http://dx.doi.org/10.1016/j.drudis.2013.05.016|
|Appears in Collections:||Published Articles (Chemical Engineering)|
Files associated with this item:
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.